Literature DB >> 28911072

Oncologist use and perception of large panel next-generation tumor sequencing.

A M Schram1, D Reales2, J Galle2, R Cambria2, R Durany3, D Feldman1,4, E Sherman1,4, J Rosenberg1,4, G D'Andrea1,4, S Baxi1,4, Y Janjigian1,4, W Tap1,4, M Dickler1,4, J Baselga1,4,5,6, B S Taylor5,6,7, D Chakravarty6, J Gao6, N Schultz6,7, D B Solit1,4,5,6, M F Berger6,8, D M Hyman1,4.   

Abstract

BACKGROUND: Genomic profiling is increasingly incorporated into oncology research and the clinical care of cancer patients. We sought to determine physician perception and use of enterprise-scale clinical sequencing at our center, including whether testing changed management and the reasoning behind this decision-making. PATIENTS AND METHODS: All physicians who consented patients to MSK-IMPACT, a next-generation hybridization capture assay, in tumor types where molecular profiling is not routinely performed were asked to complete a questionnaire for each patient. Physician determination of genomic 'actionability' was compared to an expertly curated knowledgebase of somatic variants. Reported management decisions were compared to chart review.
RESULTS: Responses were received from 146 physicians pertaining to 1932 patients diagnosed with 1 of 49 cancer types. Physicians indicated that sequencing altered management in 21% (331/1593) of patients in need of a treatment change. Among those in whom treatment was not altered, physicians indicated the presence of an actionable alteration in 55% (805/1474), however, only 45% (362/805) of these cases had a genomic variant annotated as actionable by expert curators. Further evaluation of these patients revealed that 66% (291/443) had a variant in a gene associated with biologic but not clinical evidence of actionability or a variant of unknown significance in a gene with at least one known actionable alteration. Of the cases annotated as actionable by experts, physicians identified an actionable alteration in 81% (362/445). In total, 13% (245/1932) of patients were enrolled to a genomically matched trial.
CONCLUSION: Although physician and expert assessment differed, clinicians demonstrate substantial awareness of the genes associated with potential actionability and report using this knowledge to inform management in one in five patients. CLINICAL TRIAL NUMBER: NCT01775072.
© The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  next-generation sequencing; precision medicine; targeted therapy; tumor sequencing

Mesh:

Year:  2017        PMID: 28911072      PMCID: PMC5834089          DOI: 10.1093/annonc/mdx294

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  14 in total

1.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

Review 2.  Implementing Genome-Driven Oncology.

Authors:  David M Hyman; Barry S Taylor; José Baselga
Journal:  Cell       Date:  2017-02-09       Impact factor: 41.582

3.  AKT Inhibition in Solid Tumors With AKT1 Mutations.

Authors:  David M Hyman; Lillian M Smyth; Mark T A Donoghue; Shannon N Westin; Philippe L Bedard; Emma J Dean; Hideaki Bando; Anthony B El-Khoueiry; José A Pérez-Fidalgo; Alain Mita; Jan H M Schellens; Matthew T Chang; Jonathan B Reichel; Nancy Bouvier; S Duygu Selcuklu; Tara E Soumerai; Jean Torrisi; Joseph P Erinjeri; Helen Ambrose; J Carl Barrett; Brian Dougherty; Andrew Foxley; Justin P O Lindemann; Robert McEwen; Martin Pass; Gaia Schiavon; Michael F Berger; Sarat Chandarlapaty; David B Solit; Udai Banerji; José Baselga; Barry S Taylor
Journal:  J Clin Oncol       Date:  2017-05-10       Impact factor: 44.544

4.  Institutional implementation of clinical tumor profiling on an unselected cancer population.

Authors:  Lynette M Sholl; Khanh Do; Priyanka Shivdasani; Ethan Cerami; Adrian M Dubuc; Frank C Kuo; Elizabeth P Garcia; Yonghui Jia; Phani Davineni; Ryan P Abo; Trevor J Pugh; Paul van Hummelen; Aaron R Thorner; Matthew Ducar; Alice H Berger; Mizuki Nishino; Katherine A Janeway; Alanna Church; Marian Harris; Lauren L Ritterhouse; Joshua D Campbell; Vanesa Rojas-Rudilla; Azra H Ligon; Shakti Ramkissoon; James M Cleary; Ursula Matulonis; Geoffrey R Oxnard; Richard Chao; Vanessa Tassell; James Christensen; William C Hahn; Philip W Kantoff; David J Kwiatkowski; Bruce E Johnson; Matthew Meyerson; Levi A Garraway; Geoffrey I Shapiro; Barrett J Rollins; Neal I Lindeman; Laura E MacConaill
Journal:  JCI Insight       Date:  2016-11-17

5.  Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.

Authors:  Himisha Beltran; Kenneth Eng; Juan Miguel Mosquera; Alexandros Sigaras; Alessandro Romanel; Hanna Rennert; Myriam Kossai; Chantal Pauli; Bishoy Faltas; Jacqueline Fontugne; Kyung Park; Jason Banfelder; Davide Prandi; Neel Madhukar; Tuo Zhang; Jessica Padilla; Noah Greco; Terra J McNary; Erick Herrscher; David Wilkes; Theresa Y MacDonald; Hui Xue; Vladimir Vacic; Anne-Katrin Emde; Dayna Oschwald; Adrian Y Tan; Zhengming Chen; Colin Collins; Martin E Gleave; Yuzhuo Wang; Dimple Chakravarty; Marc Schiffman; Robert Kim; Fabien Campagne; Brian D Robinson; David M Nanus; Scott T Tagawa; Jenny Z Xiang; Agata Smogorzewska; Francesca Demichelis; David S Rickman; Andrea Sboner; Olivier Elemento; Mark A Rubin
Journal:  JAMA Oncol       Date:  2015-07       Impact factor: 31.777

6.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.

Authors:  Donavan T Cheng; Talia N Mitchell; Ahmet Zehir; Ronak H Shah; Ryma Benayed; Aijazuddin Syed; Raghu Chandramohan; Zhen Yu Liu; Helen H Won; Sasinya N Scott; A Rose Brannon; Catherine O'Reilly; Justyna Sadowska; Jacklyn Casanova; Angela Yannes; Jaclyn F Hechtman; Jinjuan Yao; Wei Song; Dara S Ross; Alifya Oultache; Snjezana Dogan; Laetitia Borsu; Meera Hameed; Khedoudja Nafa; Maria E Arcila; Marc Ladanyi; Michael F Berger
Journal:  J Mol Diagn       Date:  2015-03-20       Impact factor: 5.568

7.  Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.

Authors:  Funda Meric-Bernstam; Lauren Brusco; Kenna Shaw; Chacha Horombe; Scott Kopetz; Michael A Davies; Mark Routbort; Sarina A Piha-Paul; Filip Janku; Naoto Ueno; David Hong; John De Groot; Vinod Ravi; Yisheng Li; Raja Luthra; Keyur Patel; Russell Broaddus; John Mendelsohn; Gordon B Mills
Journal:  J Clin Oncol       Date:  2015-05-26       Impact factor: 44.544

8.  Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials.

Authors:  David M Hyman; David B Solit; Maria E Arcila; Donavan T Cheng; Paul Sabbatini; Jose Baselga; Michael F Berger; Marc Ladanyi
Journal:  Drug Discov Today       Date:  2015-08-28       Impact factor: 7.851

9.  Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.

Authors:  Christophe Le Tourneau; Jean-Pierre Delord; Anthony Gonçalves; Céline Gavoille; Coraline Dubot; Nicolas Isambert; Mario Campone; Olivier Trédan; Marie-Ange Massiani; Cécile Mauborgne; Sebastien Armanet; Nicolas Servant; Ivan Bièche; Virginie Bernard; David Gentien; Pascal Jezequel; Valéry Attignon; Sandrine Boyault; Anne Vincent-Salomon; Vincent Servois; Marie-Paule Sablin; Maud Kamal; Xavier Paoletti
Journal:  Lancet Oncol       Date:  2015-09-03       Impact factor: 41.316

10.  Physicians' attitudes about multiplex tumor genomic testing.

Authors:  Stacy W Gray; Katherine Hicks-Courant; Angel Cronin; Barrett J Rollins; Jane C Weeks
Journal:  J Clin Oncol       Date:  2014-03-24       Impact factor: 44.544

View more
  11 in total

Review 1.  Histology-agnostic drug development - considering issues beyond the tissue.

Authors:  Roberto Carmagnani Pestana; Shiraj Sen; Brian P Hobbs; David S Hong
Journal:  Nat Rev Clin Oncol       Date:  2020-06-11       Impact factor: 66.675

Review 2.  Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology.

Authors:  Jessica J Tao; Alison M Schram; David M Hyman
Journal:  Annu Rev Med       Date:  2017-11-09       Impact factor: 13.739

Review 3.  Clinical cancer genomic profiling.

Authors:  Debyani Chakravarty; David B Solit
Journal:  Nat Rev Genet       Date:  2021-03-24       Impact factor: 53.242

4.  Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors.

Authors:  Coren A Milbury; James Creeden; Wai-Ki Yip; David L Smith; Varun Pattani; Kristi Maxwell; Bethany Sawchyn; Ole Gjoerup; Wei Meng; Joel Skoletsky; Alvin D Concepcion; Yanhua Tang; Xiaobo Bai; Ninad Dewal; Pei Ma; Shannon T Bailey; James Thornton; Dean C Pavlick; Garrett M Frampton; Daniel Lieber; Jared White; Christine Burns; Christine Vietz
Journal:  PLoS One       Date:  2022-03-16       Impact factor: 3.240

5.  Precision oncology: separating the wheat from the chaff.

Authors:  Jordi Remon; Rodrigo Dienstmann
Journal:  ESMO Open       Date:  2018-10-30

6.  Treatment recommendations to cancer patients in the context of FDA guidance for next generation sequencing.

Authors:  Grace K Dy; Mary K Nesline; Antonios Papanicolau-Sengos; Paul DePietro; Charles M LeVea; Amy Early; Hongbin Chen; Anne Grand'Maison; Patrick Boland; Marc S Ernstoff; Stephen Edge; Stacey Akers; Mateusz Opyrchal; Gurkamal Chatta; Kunle Odunsi; Sarabjot Pabla; Jeffrey M Conroy; Sean T Glenn; Hanchun T DeFedericis; Blake Burgher; Jonathan Andreas; Vincent Giamo; Maochun Qin; Yirong Wang; Kazunori Kanehira; Felicia L Lenzo; Peter Frederick; Shashikant Lele; Lorenzo Galluzzi; Boris Kuvshinoff; Carl Morrison
Journal:  BMC Med Inform Decis Mak       Date:  2019-01-18       Impact factor: 2.796

7.  Cancer Panel Assay for Precision Oncology Clinic: Results from a 1-Year Study.

Authors:  Dohee Kwon; Binnari Kim; Hyeong Chan Shin; Eun Ji Kim; Sang Yun Ha; Kee-Taek Jang; Seung Tae Kim; Jeeyun Lee; Won Ki Kang; Joon Oh Park; Kyoung-Mee Kim
Journal:  Transl Oncol       Date:  2019-08-20       Impact factor: 4.243

Review 8.  Implementation of genomic medicine for gastrointestinal tumors.

Authors:  Yoichi Furukawa
Journal:  Ann Gastroenterol Surg       Date:  2018-06-08

Review 9.  A Review of Precision Oncology Knowledgebases for Determining the Clinical Actionability of Genetic Variants.

Authors:  Xuanyi Li; Jeremy L Warner
Journal:  Front Cell Dev Biol       Date:  2020-02-11

10.  Real-World Outcomes of an Automated Physician Support System for Genome-Driven Oncology.

Authors:  Jessica J Tao; Michael H Eubank; Alison M Schram; Nicholas Cangemi; Erika Pamer; Ezra Y Rosen; Nikolaus Schultz; Debyani Chakravarty; John Philip; Jaclyn F Hechtman; James J Harding; Lillian M Smyth; Komal L Jhaveri; Alexander Drilon; Marc Ladanyi; David B Solit; Ahmet Zehir; Michael F Berger; Peter D Stetson; Stuart M Gardos; David M Hyman
Journal:  JCO Precis Oncol       Date:  2019-07-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.